Track the Akouos, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 2 December 2022 (U). Among the most active insiders: Preston Heather. Every trade is free.
17
Insider Decl.
n/a
Thresholds
€363m
1 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Akouos, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
14Σ signal
Buys €363mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
29,992,668 shares@ US$12.50100.0% of flowCommon StockSEC:0000899243-22-037279:0
Canonical exit: 28 Feb 2023 (T+90)
17 of 17 declarations
About Akouos, Inc.
Akouos, Inc. is a biopharmaceutical company focused on developing gene therapies to treat hearing disorders. It is listed on the NASDAQ under the ticker symbol AKUS.